Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Dry Eye Disease (DED): later-stage trial registry
1 of 4 indexed Dry Eye Disease (DED) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Dry Eye Disease (DED): 4 US clinical trials tracked, 1 recruiting.
Dry Eye Disease (DED) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Oyster Point Pharma, running 1 of these trials.
Enrollment posture brief
Registry condition dry-eye-disease-ded
OPEN 1 | RECR 25% | LATE 3 | EARLY 0 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Dry Eye Disease (DED) lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Dry Eye Disease (DED) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Dry Eye Disease (DED) is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery
Vance Thompson Vision
NCT07155057
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Oyster Point Pharma
NCT04036292
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Allergan
NCT04393441
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
Bausch & Lomb Incorporated
NCT04140227
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Dry Eye Disease (DED) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Dry Eye Disease (DED) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Dry Eye Disease (DED) page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Dry Eye Disease (DED) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Oyster Point Pharma sponsors the most Dry Eye Disease (DED) trials on record, review their full trial history before evaluating a specific study. See Oyster Point Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dry Eye Disease (DED) condition card totals 4 registered trials; most-linked intervention OC-01 (varenicline) nasal spray; top US site state Kentucky. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.